Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9304492 | 0.88 | TSHR (0.54) | SPHK1MEN1KMT2ATP53TSHR | |
| SCHEMBL106428 | 0.85 | SPHK1 (0.50) | SPHK1MEN1KMT2ATP53TSHR | |
| SCHEMBL19026945 | 0.84 | SPHK1 (0.50) | SPHK1MEN1KMT2AGAAMAPT | |
| SCHEMBL169899 | 0.82 | GAA (0.44) | SPHK1GAAMAPTGFERTP53 | |
| SCHEMBL28511551 | 0.82 | MEN1 (0.47) | SPHK1MEN1KMT2ALMNA | |
| SCHEMBL28521165 | 0.82 | NPC1 (0.56) | SPHK1GAAMAPTTSHRHSD17B10 | |
| SCHEMBL407809 | 0.82 | ALDH1A1 (0.56) | SPHK1GAASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL8238318 | 0.82 | KIF11 (0.51) | SPHK1ALDH1A1LMNA | |
| SCHEMBL14817483 | 0.81 | NAPRT (0.53) | SPHK1MEN1KMT2AGAAMAPT | |
| SCHEMBL138295 | 0.81 | MEN1 (0.51) | SPHK1MEN1KMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | claimed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | claimed |
| EP-1377589-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | claimed |
| WO-2002062804-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-15 | — | — | WO | claimed |
| US-20260138953-A1 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | HANDA ONCOLOGY, LLC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12552749-B2 | Cabozantinib compositions and methods of use | HANDA ONCOLOGY, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-12522567-B2 | Cabozantinib compositions and methods of use | HANDA ONCOLOGY, LLC (US) | 2026-01-13 | — | — | US | disclosed |
| US-12516025-B2 | Cabozantinib compositions and methods of use | HANDA ONCOLOGY, LLC (US) | 2026-01-06 | — | — | US | disclosed |
| US-12415784-B2 | Cabozantinib compositions and methods of use | HANDA ONCOLOGY, LLC (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250257036-A1 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | HANDA ONCOLOGY, LLC (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250250238-A1 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | HANDA ONCOLOGY, LLC (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250243166-A1 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | HANDA ONCOLOGY, LLC (US) | 2025-07-31 | — | — | US | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2008046216-A1 | KINASE INHIBITORS AND USES THEREOF | METHYLGENE, INC. (CA) | 2008-04-24 | — | — | WO | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-4009278-A | Antimicrobial composition and method containing N-(3,5-dihalophenyl)-imide compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | SPHK1 1186/4885MEN1 1228/4885KMT2A 977/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | SPHK1 1254/4885MEN1 3655/4885KMT2A 3391/4885 |
| US-12415784-B2 | Cabozantinib compositions and methods of use | KRAS, GSK3B, KSR2 | SPHK1 415/4885MEN1 1975/4885KMT2A 1055/4885 |
| US-20250250238-A1 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | KRAS, GSK3B, KSR2 | SPHK1 415/4885MEN1 1975/4885KMT2A 1055/4885 |
| US-20260138953-A1 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | CTNND1, CSNK1D, SLC34A2 | SPHK1 651/4885MEN1 3918/4885KMT2A 2350/4885 |
| US-20250243166-A1 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | KRAS, GSK3B, KSR2 | SPHK1 415/4885MEN1 1975/4885KMT2A 1055/4885 |
| US-12552749-B2 | Cabozantinib compositions and methods of use | SI, CCNB1, GYS1 | SPHK1 294/4885MEN1 392/4885KMT2A 1461/4885 |
| US-20250257036-A1 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | KRAS, GSK3B, KSR2 | SPHK1 415/4885MEN1 1975/4885KMT2A 1055/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | SPHK1 882/4885MEN1 1410/4885KMT2A 732/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | SPHK1 846/4885MEN1 1333/4885KMT2A 769/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | SPHK1 846/4885MEN1 1333/4885KMT2A 769/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | SPHK1 882/4885MEN1 1410/4885KMT2A 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.